Volume 18, Number 2—February 2012
Research
Effect of Surveillance Method on Reported Characteristics of Lyme Disease, Connecticut, 1996–2007
Starr-Hope Ertel
, Randall S. Nelson, and Matthew L. Cartter
, Randall S. Nelson, and Matthew L. Cartter
Table 4
Late manifestations of Lyme disease, by surveillance method, Connecticut, 1996–2007*
| Manifestation† | No. cases (%) |
||||
|---|---|---|---|---|---|
| PS, n = 2,059 | AS, n = 1,725 | ELS, n = 763 | MLS, n = 4,678 | Total, n = 9,225 | |
| Lyme arthritis | 1,448 (70.3) | 1,353 (78.4) | 532 (69.7) | 3,318 (70.9) | 6,651 (72.1) |
| Bell palsy | 454 (22.1) | 259 (15.0) | 143 (18.7) | 814 (17.4) | 1,670 (18.1) |
| Radiculoneuropathy | 117 (5.7) | 131 (7.6) | 84 (11.0) | 501 (10.7) | 833 (9.0) |
| Lymphocytic meningitis | 61 (3.0) | 35 (2.0) | 19 (2.5) | 108 (2.3) | 223 (2.4) |
| Encephalitis/encephalomylitis | 38 (1.5) | 18 (1.0) | 26 (3.4) | 116 (2.5) | 198 (2.1) |
| Second- or third-degree heart block | 40 (1.9) | 26 (1.5) | 10 (1.3) | 58 (1.2) | 134 (1.4) |
*PS, passive surveillance; AS, active surveillance; ELS, enhanced laboratory surveillance; MLS, mandatory laboratory surveillance.
†May have included >1 late manifestation per case. Percentages do not add to 100%.
Page created: January 19, 2012
Page updated: January 19, 2012
Page reviewed: January 19, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.